Biosensing devices such as lateral flow assays or blood glucose test strips have had a great impact on healthcare for more than half a century and have already improved our living standards. In particular, biosensors allow us to measure clinically relevant biomarkers from various sample matrices (including whole blood, plasma, saliva, or urine) in a fast, cost-effective, and user-friendly manner. Hence, biosensing technologies can provide vital information related to the propensity for illness or the status of a disease, or its treatment monitoring. However, there are still some challenges, especially regarding the sample collection and preparation as well as the biosensing performance of diagnostic devices.To further assess the potential of this technology, researchers are pushing forward the frontiers of integrated biosensors, combining the sample collection, preparation, analysis, and data evaluation, to create "sample-in-answer-out" diagnostic devices. Such integrated solutions for biosensing could enable real-time, highly sensitive, and selective quantification of various biomolecules within clinically relevant body fluids in a smart, sustainable, interoperable, and portable manner. This Research Topic gathers innovative approaches for integrated biosensing systems conceived from colleagues located in diverse parts of the world, including Australia, China, Denmark, Taiwan, the United Kingdom, and the United States. Several clinically relevant agents are targeted, including In addition, the portable character and geo-tagging abilities of the platform were proven to be 69 technically sound in low-resource settings employing a pilot study performed between UK and Taiwan.We hope this article collection contributes valuable insights into the exciting field of integrated 71 biosensors with comprehensive knowledge of fundamentals, materials, technologies, and their point-72 of-care applications. This in turn will help researchers to conduct research beyond the state-of-the-art 73 in this field. 74
Editorial12 September 2022
Editorial: Integrated biosensors towards clinical and point-of-care diagnostics
ORIGINAL RESEARCH
26 November 2021
Mohammad Rahbar, 2 more and Guozhen Liu
4 Authors
- MR
Mohammad Rahbar
Graduate School of Biomedical Engineering, The University of New South Wales, Australia
- YW
Yuling Wu
Integrated Bioanalysis, Clinical Pharmacology and Quantitative Pharmacology, BioPharmaceuticals R&D, AstraZeneca, United States
- JA
J. Anand Subramony
Biologics Engineering R&D, AstraZeneca, United States
- GL
Guozhen Liu
Graduate School of Biomedical Engineering, The University of New South Wales, Australia
Interleukin-6 (IL-6) is a pro/anti-inflammatory cytokine, the quantitative detection of which has been extensively considered for diagnosis of inflammatory associated diseases. However, there has not yet been a reliable, low-cost, and user-friendly platform developed for point-of-care (POC) detection of IL-6, which will eliminate the conventional costly, time-consuming, and complex assays. In this work, we developed a lateral flow assay (LFA) for colorimetric detection of IL-6, using anti-IL-6 antibodies conjugated to gold nanoparticles (AuNPs) as the detection probes. Silver amplification technique was incorporated with the newly developed assay in order to enhance the obtained colorimetric signals, allowing sensitive detection of IL-6 in human serum in the desired physiological ranges (i.e. 5-1000 pg/mL). A limit of detection (LOD) of 5 pg/mL could be achieved for IL-6 detection in serum with the amplification step which was not achievable in the standard assay. The corresponding specificity and reproducibility tests were all preformed to confirm the reliability of this assay for quantitative measurement of IL-6 in a POC manner.